Acorn Capital Advisors’s UroGen Pharma URGN Stock Holding History

Acorn Capital Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.1M	Buy	1,673,420 +225,000	+16%	+$4.51M	8.55%	3
2025 Q4	$33.9M	Buy	1,448,420 +188,671	+15%	+$4.09M	11.49%	3
2025 Q3	$25.1M	Hold	1,259,749	–	–	12.76%	2
2025 Q2	$17.3M	Sell	1,259,749 -256,554	-17%	-$2.46M	11.29%	2
2025 Q1	$16.8M	Hold	1,516,303	–	–	11.18%	2
2024 Q4	$16.1M	Buy	+1,516,303	New	+$18.2M	8.69%	4

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Acorn Capital Advisors's URGN Position: Q1 2026 in Review

Acorn Capital Advisors increased its UroGen Pharma (URGN) stake by 16% in Q1 2026, buying an estimated $4.51M and bringing the position to 1,673,420 shares worth $30.1M. The position accounts for 8.55% of the portfolio, ranked #3.

Acorn Capital Advisors first reported a position in URGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $33.9M in Q4 2025. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

Acorn Capital Advisors held 1,673,420 shares of UroGen Pharma worth $30.1M as of Q1 2026.
Acorn Capital Advisors bought 225,000 UroGen Pharma shares in Q1 2026, an estimated $4.51M.
UroGen Pharma made up 8.55% of Acorn Capital Advisors's portfolio in Q1 2026, its #3 holding.
Acorn Capital Advisors first reported a position in UroGen Pharma in Q4 2024 and has held it in 6 quarters since.
Acorn Capital Advisors's UroGen Pharma position peaked at $33.9M in Q4 2025.
173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Acorn Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.